Heteroconjugate antibodies for treatment of hiv infection

Details Heteroconjugate antibodies for treatment of hiv infection Heteroconjugate antibodies for treatment of hiv infection

A - Human Necessities

61

K

A61K 39/42 (2006.01) A61K 35/14 (2006.01) C07K 16/46 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2102511

2102511 9220373 PCTABS00017 The invention features a heteroconjugate antibody which includes two binding functionalities. The first binding function is directed to a peripheral blood effector cell antigen, preferably CD-3. The second functionality is directed to a specific domain of an aids virus coat protein, preferably the V3 loop sequence of the gp120 envelope from HIV MN or a variant thereof. Methods of therapy are also presented where 20 ng/ml of a mixed culture of HIV infected cells (effector/CEM-ss cells) have a 80-90 % decrease in reverse transcriptase activity compared to an identical culture with a 3:1 ratio of effector cell:CEM-ss.

Affiliated with

Also associated with

Rating

Heteroconjugate antibodies for treatment of hiv infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroconjugate antibodies for treatment of hiv infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroconjugate antibodies for treatment of hiv infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1662163